Continuing Ovarian Suppression After 5 Years
Part of Cancer, Skin clinical trials.
This trial checks if staying on ovarian function suppression (OFS) therapy beyond 5 years helps prevent breast cancer from coming back. It's for women with early-stage, hormone-sensitive (HR+ HER2-) breast cancer who have already completed 5 years of OFS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage breast cancer (cancer that hasn't spread far).
- You are a woman between 18 and 60 years old.
- Your cancer is hormone receptor-positive and HER2-negative.
- You have already been on ovarian function suppression (OFS) therapy for 5 years.
- You are in good general health (able to do daily activities with little or no help).
- You agree to join the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well women with hormone receptor-positive breast cancer follow the plan for ovarian suppression therapy (medication to lower estrogen). It aims to help doctors understand real-world treatment patterns and improve care.
This study tests whether switching the type of ovarian-suppressing medication helps keep hormone-sensitive breast cancer under control in younger women. You'll be screened to see if your current treatment is working, then potentially switched to a different formulation to see if it works better.
This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.
This trial tests a new blood-based test (OCS) that looks for tiny particles from tumor cells to watch for cancer returning after initial treatment. It is for women with ovarian cancer whose CA125 levels were normal before starting treatment.
This Phase 3 trial tests whether ongoing treatment with an aromatase inhibitor (a hormone-blocking medicine) after initial chemotherapy can help keep epithelial ovarian/fallopian tube/peritoneal cancer from coming back. It is only for certain tumor types that are hormone-receptor positive (ER+).
This trial tests if taking hormone therapy for 5 more years helps prevent breast cancer from coming back. It is for women who have already completed 5 years of tamoxifen or an aromatase inhibitor and had lymph node involvement at diagnosis.
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.